Tavarekere N Nagaraja1, Seamus Bartlett2,3, Katelynn G Farmer4, Glauber Cabral4, Robert A Knight4,5, O Grahm Valadie4,6, Stephen L Brown6,7, James R Ewing2,4,5,8, Ian Y Lee2. 1. Department of Neurosurgery, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI, 48202-2689, USA. tnagara1@hfhs.org. 2. Department of Neurosurgery, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI, 48202-2689, USA. 3. School of Medicine, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA. 4. Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI, 48202, USA. 5. Department of Physics, Oakland University, 146 Library Drive, Rochester, MI, 48309, USA. 6. Department of Radiation Oncology, Wayne State University, 4201 St Antoine Boulevard, Detroit, MI, 48201, USA. 7. Department of Radiation Oncology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI, 48202, USA. 8. Department of Neurology, Wayne State University, 4201 St Antoine Boulevard, Detroit, MI, 48201, USA.
Abstract
BACKGROUND: Laser interstitial thermal therapy (LITT) under magnetic resonance imaging (MRI) monitoring is being increasingly used in cytoreductive surgery of recurrent brain tumors and tumors located in eloquent brain areas. The objective of this study was to adapt this technique to an animal glioma model. METHODS: A rat model of U251 glioblastoma (GBM) was employed. Tumor location and extent were determined by MRI and dynamic contrast-enhanced (DCE) MRI. A day after assessing tumor appearance, tumors were ablated during diffusion-weighted imaging (DWI)-MRI using a Visualase LITT system (n = 5). Brain images were obtained immediately after ablation and again at 24 h post-ablation to confirm the efficacy of tumor cytoablation. Untreated tumors served as controls (n = 3). Rats were injected with fluorescent isothiocyanate (FITC) dextran and Evans blue that circulated for 10 min after post-LITT MRI. The brains were then removed for fluorescence microscopy and histopathology evaluations using hematoxylin and eosin (H&E) and major histocompatibility complex (MHC) staining. RESULTS: All rats showed a space-occupying tumor with T2 and T1 contrast-enhancement at pre-LITT imaging. The rats that underwent the LITT procedure showed a well-demarcated ablation zone with near-complete ablation of tumor tissue and with peri-ablation contrast enhancement at 24 h post-ablation. Tumor cytoreduction by ablation as seen on MRI was confirmed by H&E and MHC staining. CONCLUSIONS: Data showed that tumor cytoablation using MRI-monitored LITT was possible in preclinical glioma models. Real-time MRI monitoring facilitated visualizing and controlling the area of ablation as it is otherwise performed in clinical applications.
BACKGROUND: Laser interstitial thermal therapy (LITT) under magnetic resonance imaging (MRI) monitoring is being increasingly used in cytoreductive surgery of recurrent brain tumors and tumors located in eloquent brain areas. The objective of this study was to adapt this technique to an animal glioma model. METHODS: A rat model of U251 glioblastoma (GBM) was employed. Tumor location and extent were determined by MRI and dynamic contrast-enhanced (DCE) MRI. A day after assessing tumor appearance, tumors were ablated during diffusion-weighted imaging (DWI)-MRI using a Visualase LITT system (n = 5). Brain images were obtained immediately after ablation and again at 24 h post-ablation to confirm the efficacy of tumor cytoablation. Untreated tumors served as controls (n = 3). Rats were injected with fluorescent isothiocyanate (FITC) dextran and Evans blue that circulated for 10 min after post-LITT MRI. The brains were then removed for fluorescence microscopy and histopathology evaluations using hematoxylin and eosin (H&E) and major histocompatibility complex (MHC) staining. RESULTS: All rats showed a space-occupying tumor with T2 and T1 contrast-enhancement at pre-LITT imaging. The rats that underwent the LITT procedure showed a well-demarcated ablation zone with near-complete ablation of tumor tissue and with peri-ablation contrast enhancement at 24 h post-ablation. Tumor cytoreduction by ablation as seen on MRI was confirmed by H&E and MHC staining. CONCLUSIONS: Data showed that tumor cytoablation using MRI-monitored LITT was possible in preclinical glioma models. Real-time MRI monitoring facilitated visualizing and controlling the area of ablation as it is otherwise performed in clinical applications.
Authors: D F Emerich; S R Winn; Y Hu; J Marsh; P Snodgrass; D LaFreniere; T Wiens; B P Hasler; R T Bartus Journal: Pharm Res Date: 2000-07 Impact factor: 4.200
Authors: Rasha Elmghirbi; Tavarekere N Nagaraja; Stephen L Brown; Kelly A Keenan; Swayamprava Panda; Glauber Cabral; Hassan Bagher-Ebadian; George W Divine; Ian Y Lee; James R Ewing Journal: Magn Reson Med Date: 2018-03-09 Impact factor: 4.668
Authors: Richard Rammo; Karam Asmaro; Lonni Schultz; Lisa Scarpace; Salim Siddiqui; Tobias Walbert; Steven Kalkanis; Ian Lee Journal: J Neurooncol Date: 2018-03-13 Impact factor: 4.130
Authors: Stephen L Brown; Tavarekere N Nagaraja; Madhava P Aryal; Swayamprava Panda; Glauber Cabral; Kelly Ann Keenan; Rasha Elmghirbi; Tom Mikkelsen; David Hearshen; Robert A Knight; Ning Wen; Jae Ho Kim; James R Ewing Journal: Radiat Res Date: 2015-05-26 Impact factor: 2.841
Authors: Tavarekere N Nagaraja; Madhava P Aryal; Stephen L Brown; Hassan Bagher-Ebadian; Tom Mikkelsen; James J Yang; Swayamprava Panda; Kelly A Keenan; Glauber Cabral; James R Ewing Journal: PLoS One Date: 2013-12-23 Impact factor: 3.240